{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:14:13Z","timestamp":1791828853919,"version":"4.3.4"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11897-024-00682-w","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T12:30:29Z","timestamp":1726662629000},"page":"530-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Heart Failure in Rheumatoid Arthritis: Clinical Implications"],"prefix":"10.1007","volume":"21","author":[{"given":"Alexis","family":"Zambrano Zambrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Del R\u00edo Zanatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gonz\u00e1lez Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Bernal Alferes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Zambrano Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Martinez Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Haroldo","family":"Ixcamparij Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"issue":"6","key":"682_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra2103726","volume":"388","author":"EM Gravallese","year":"2023","unstructured":"Gravallese EM, Firestein GS. Rheumatoid arthritis - common origins, divergent mechanisms. N Engl J Med. 2023;388(6):529\u201342. https:\/\/doi.org\/10.1056\/NEJMra2103726.","journal-title":"N Engl J Med"},{"issue":"11","key":"682_CR2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41584-020-0503-4","volume":"16","author":"M Cutolo","year":"2020","unstructured":"Cutolo M, Straub RH. Sex steroids and autoimmune rheumatic diseases: state of the art. Nat Rev Rheumatol. 2020;16(11):628\u201344. https:\/\/doi.org\/10.1038\/s41584-020-0503-4.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"682_CR3","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/acr.24804","volume":"75","author":"S Huang","year":"2023","unstructured":"Huang S, Cai T, Weber BN, et al. Association between inflammation, incident heart failure, and heart failure subtypes in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2023;75(5):1036\u201345. https:\/\/doi.org\/10.1002\/acr.24804.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"20","key":"682_CR4","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1136\/heartjnl-2019-316193","volume":"106","author":"E Nikiphorou","year":"2020","unstructured":"Nikiphorou E, de Lusignan S, Mallen CD, et al. Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study. Heart. 2020;106(20):1566\u201372. https:\/\/doi.org\/10.1136\/heartjnl-2019-316193.","journal-title":"Heart"},{"issue":"2","key":"682_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/art.20855","volume":"52","author":"PJ Nicola","year":"2005","unstructured":"Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52(2):412\u201320. https:\/\/doi.org\/10.1002\/art.20855.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"682_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.rdc.2022.08.003","volume":"49","author":"BB L\u00f8gstrup","year":"2023","unstructured":"L\u00f8gstrup BB. Heart failure in rheumatic disease: secular trends and novel insights. Rheum Dis Clin North Am. 2023;49(1):67\u201379. https:\/\/doi.org\/10.1016\/j.rdc.2022.08.003.","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"682_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/ard-2022-223315","volume":"82","author":"N Conrad","year":"2023","unstructured":"Conrad N, McInnes IB, Mcmurray JJV, Sattar N. Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)\u2019s recommendations for cardiovascular risk management? Ann Rheum Dis. 2023;82(4):457\u20139. https:\/\/doi.org\/10.1136\/ard-2022-223315.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"682_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13075-022-02864-0","volume":"24","author":"E Park","year":"2022","unstructured":"Park E, Ito K, Iqbal R, et al. Prospective changes in diastolic function in patients with rheumatoid arthritis. Arthritis Res Ther. 2022;24(1):184. https:\/\/doi.org\/10.1186\/s13075-022-02864-0. Published 2022 Aug 5.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"682_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12574-022-00583-8","volume":"21","author":"VK Thallapally","year":"2023","unstructured":"Thallapally VK, Bansal R, Thandra A, et al. Detection of myocardial dysfunction using global longitudinal strain with speckle-tracking echocardiography in patients with vs without rheumatoid arthritis: a systematic review and meta-analysis. J Echocardiogr. 2023;21(1):23\u201332. https:\/\/doi.org\/10.1007\/s12574-022-00583-8.","journal-title":"J Echocardiogr"},{"issue":"36","key":"682_CR10","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J. 2021]. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"key":"682_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ahj.2023.02.001","volume":"259","author":"J Fax\u00e9n","year":"2023","unstructured":"Fax\u00e9n J, Benson L, Mantel \u00c4, et al. Associations between rheumatoid arthritis, incident heart failure, and left ventricular ejection fraction. Am Heart J. 2023;259:42\u201351. https:\/\/doi.org\/10.1016\/j.ahj.2023.02.001.","journal-title":"Am Heart J"},{"issue":"10","key":"682_CR12","doi-asserted-by":"publisher","first-page":"e014661","DOI":"10.1161\/JAHA.119.014661","volume":"9","author":"MJ Ahlers","year":"2020","unstructured":"Ahlers MJ, Lowery BD, Farber-Eger E, et al. Heart failure risk associated with rheumatoid arthritis-related chronic inflammation. J Am Heart Assoc. 2020;9(10):e014661. https:\/\/doi.org\/10.1161\/JAHA.119.014661.","journal-title":"J Am Heart Assoc"},{"key":"682_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejim.2020.11.002","volume":"85","author":"MB Ferreira","year":"2021","unstructured":"Ferreira MB, Fonseca T, Costa R, et al. Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: the RA-HF study. Eur J Intern Med. 2021;85:41\u20139. https:\/\/doi.org\/10.1016\/j.ejim.2020.11.002.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"682_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s43044-022-00319-0","volume":"74","author":"S Norouzi","year":"2022","unstructured":"Norouzi S, Khalaji A, Namazi M, Rezaei SS, Behnoush AH, Masoumi M. Ventricular and atrial function assessment with transthoracic echocardiography in patients with rheumatic inflammatory disease. Egypt Heart J. 2022;74(1):81. https:\/\/doi.org\/10.1186\/s43044-022-00319-0. Published 2022 Nov 25.","journal-title":"Egypt Heart J"},{"issue":"6","key":"682_CR15","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1002\/ehf2.12947","volume":"7","author":"Y Khalid","year":"2020","unstructured":"Khalid Y, Dasu N, Shah A, et al. Incidence of congestive heart failure in rheumatoid arthritis: a review of literature and meta-regression analysis. ESC Heart Fail. 2020;7(6):3745\u201353. https:\/\/doi.org\/10.1002\/ehf2.12947.","journal-title":"ESC Heart Fail"},{"issue":"18","key":"682_CR16","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","volume":"81","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC Scientific Statement. J Am Coll Cardiol. 2023;81(18):1810\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2023.01.049.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"682_CR17","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3899\/jrheum.100979","volume":"38","author":"E Myasoedova","year":"2011","unstructured":"Myasoedova E, Crowson CS, Nicola PJ, et al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol. 2011;38(8):1601\u20136. https:\/\/doi.org\/10.3899\/jrheum.100979.","journal-title":"J Rheumatol"},{"issue":"10","key":"682_CR18","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.jacc.2016.12.033","volume":"69","author":"\u00c4 Mantel","year":"2017","unstructured":"Mantel \u00c4, Holmqvist M, Andersson DC, Lund LH, Askling J. Association between rheumatoid arthritis and Risk of ischemic and nonischemic heart failure. J Am Coll Cardiol. 2017;69(10):1275\u201385. https:\/\/doi.org\/10.1016\/j.jacc.2016.12.033.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"682_CR19","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/ejhf.414","volume":"17","author":"S Sanders-van Wijk","year":"2015","unstructured":"Sanders-van Wijk S, van Empel V, Davarzani N, et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail. 2015;17(10):1006\u201314. https:\/\/doi.org\/10.1002\/ejhf.414.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"682_CR20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/art.41979","volume":"74","author":"E Park","year":"2022","unstructured":"Park E, Griffin J, Bathon JM. Myocardial dysfunction and heart failure in rheumatoid arthritis. Arthritis Rheumatol. 2022;74(2):184\u201399. https:\/\/doi.org\/10.1002\/art.41979.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"682_CR21","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3390\/cells10040881","volume":"10","author":"J Chen","year":"2021","unstructured":"Chen J, Norling LV, Cooper D. Cardiac Dysfunction in rheumatoid arthritis: the role of inflammation. Cells. 2021;10(4):881. https:\/\/doi.org\/10.3390\/cells10040881. Published 2021 Apr 13.","journal-title":"Cells"},{"issue":"2","key":"682_CR22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00424-002-0921-y","volume":"445","author":"A Combes","year":"2002","unstructured":"Combes A, Frye CS, Lemster BH, et al. Chronic exposure to interleukin 1beta induces a delayed and reversible alteration in excitation-contraction coupling of cultured cardiomyocytes. Pflugers Arch. 2002;445(2):246\u201356. https:\/\/doi.org\/10.1007\/s00424-002-0921-y.","journal-title":"Pflugers Arch"},{"issue":"1","key":"682_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1161\/CIRCHEARTFAILURE.109.931451","volume":"4","author":"D Westermann","year":"2011","unstructured":"Westermann D, Lindner D, Kasner M, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail. 2011;4(1):44\u201352. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.109.931451.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"682_CR24","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1016\/j.ijcard.2013.05.085","volume":"168","author":"S Mavrogeni","year":"2013","unstructured":"Mavrogeni S, Karabela G, Stavropoulos E, et al. Imaging patterns of heart failure in rheumatoid arthritis evaluated by cardiovascular magnetic resonance. Int J Cardiol. 2013;168(4):4333\u20135. https:\/\/doi.org\/10.1016\/j.ijcard.2013.05.085.","journal-title":"Int J Cardiol"},{"issue":"22","key":"682_CR25","doi-asserted-by":"publisher","first-page":"e019390","DOI":"10.1161\/JAHA.120.019390","volume":"9","author":"RB Patel","year":"2020","unstructured":"Patel RB, Colangelo LA, Bielinski SJ, et al. Circulating vascular cell adhesion molecule-1 and incident heart failure: the multi-ethnic study of atherosclerosis (MESA). J Am Heart Assoc. 2020;9(22):e019390. https:\/\/doi.org\/10.1161\/JAHA.120.019390.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"682_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/art.27264","volume":"62","author":"C Grundtman","year":"2010","unstructured":"Grundtman C, Hollan I, F\u00f8rre OT, Saatvedt K, Mikkelsen K, Lundberg IE. Cardiovascular disease in patients with inflammatory rheumatic disease is associated with up-regulation of markers of inflammation in cardiac microvessels and cardiomyocytes. Arthritis Rheum. 2010;62(3):667\u201373. https:\/\/doi.org\/10.1002\/art.27264.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"682_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/acr.24108","volume":"73","author":"KP Liao","year":"2021","unstructured":"Liao KP, Huang J, He Z, et al. Coronary microvascular dysfunction in rheumatoid arthritis compared to diabetes mellitus and association with all-cause mortality. Arthritis Care Res (Hoboken). 2021;73(2):159\u201365. https:\/\/doi.org\/10.1002\/acr.24108.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"682_CR28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/art.40771","volume":"71","author":"I Amigues","year":"2019","unstructured":"Amigues I, Tugcu A, Russo C, et al. Myocardial inflammation, measured using 18-Fluorodeoxyglucose Positron emission tomography with computed tomography, is associated with disease activity in rheumatoid arthritis. Arthritis Rheumatol. 2019;71(4):496\u2013506. https:\/\/doi.org\/10.1002\/art.40771.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 5","key":"682_CR29","doi-asserted-by":"publisher","first-page":"v29","DOI":"10.1093\/rheumatology\/kez346","volume":"58","author":"KL Druce","year":"2019","unstructured":"Druce KL, Basu N. Predictors of fatigue in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 5):v29\u201334. https:\/\/doi.org\/10.1093\/rheumatology\/kez346.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"682_CR30","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2023.2020","volume":"329","author":"MM Redfield","year":"2023","unstructured":"Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA. 2023;329(10):827\u201338. https:\/\/doi.org\/10.1001\/jama.2023.2020.","journal-title":"JAMA"},{"issue":"2","key":"682_CR31","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3899\/jrheum.130713","volume":"41","author":"J Avouac","year":"2014","unstructured":"Avouac J, Meune C, Chenevier-Gobeaux C, et al. Inflammation and disease activity are associated with high circulating cardiac markers in rheumatoid arthritis independently of traditional cardiovascular risk factors. J Rheumatol. 2014;41(2):248\u201355. https:\/\/doi.org\/10.3899\/jrheum.130713.","journal-title":"J Rheumatol"},{"issue":"20","key":"682_CR32","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1093\/eurheartj\/ehac121","volume":"43","author":"SJ Shah","year":"2022","unstructured":"Shah SJ. BNP: Biomarker not perfect in heart failure with preserved ejection fraction. Eur Heart J. 2022;43(20):1952\u20134. https:\/\/doi.org\/10.1093\/eurheartj\/ehac121.","journal-title":"Eur Heart J"},{"issue":"20","key":"682_CR33","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1093\/eurheartj\/ehab911","volume":"43","author":"FH Verbrugge","year":"2022","unstructured":"Verbrugge FH, Omote K, Reddy YNV, Sorimachi H, Obokata M, Borlaug BA. Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. Eur Heart J. 2022;43(20):1941\u201351. https:\/\/doi.org\/10.1093\/eurheartj\/ehab911.","journal-title":"Eur Heart J"},{"issue":"4","key":"682_CR34","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1136\/annrheumdis-2012-202848","volume":"73","author":"H Mirjafari","year":"2014","unstructured":"Mirjafari H, Welsh P, Verstappen SM, et al. N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). Ann Rheum Dis. 2014;73(4):684\u201390. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202848.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"682_CR35","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s10067-018-4369-7","volume":"38","author":"B Targo\u0144ska-St\u0119pniak","year":"2019","unstructured":"Targo\u0144ska-St\u0119pniak B, Biskup M, Biskup W, Majdan M. Diastolic dysfunction in rheumatoid arthritis patients with low disease activity. Clin Rheumatol. 2019;38(4):1131\u20137. https:\/\/doi.org\/10.1007\/s10067-018-4369-7.","journal-title":"Clin Rheumatol"},{"key":"682_CR36","doi-asserted-by":"publisher","unstructured":"Pieske B, Tsch\u00f6pe C, de Boer RA et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) [published correction appears in Eur Heart J. 2021;42(13):1274]. Eur Heart J. 2019;40(40):3297\u20133317. https:\/\/doi.org\/10.1093\/eurheartj\/ehz641","DOI":"10.1093\/eurheartj\/ehz641"},{"issue":"11","key":"682_CR37","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1136\/annrheumdis-2020-217653","volume":"79","author":"S Plein","year":"2020","unstructured":"Plein S, Erhayiem B, Fent G, et al. Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-na\u00efve, early rheumatoid arthritis. Ann Rheum Dis. 2020;79(11):1414\u201322. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217653.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"682_CR38","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.echo.2017.02.001","volume":"30","author":"G Cioffi","year":"2017","unstructured":"Cioffi G, Viapiana O, Ognibeni F, et al. Prognostic role of subclinical left ventricular systolic dysfunction evaluated by speckle-tracking echocardiography in rheumatoid arthritis. J Am Soc Echocardiogr. 2017;30(6):602\u201311. https:\/\/doi.org\/10.1016\/j.echo.2017.02.001.","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"682_CR39","doi-asserted-by":"publisher","first-page":"21537","DOI":"10.1038\/s41598-021-00657-0","volume":"11","author":"X Ji","year":"2021","unstructured":"Ji X, Zhang X, Li G. A preliminary study on the evaluation of left atrial function of rheumatoid arthritis by two dimensional speckle tracking imaging. Sci Rep. 2021;11(1):21537. https:\/\/doi.org\/10.1038\/s41598-021-00657-0. Published 2021 Nov 2.","journal-title":"Sci Rep"},{"issue":"7","key":"682_CR40","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1007\/s10067-020-05544-z","volume":"40","author":"JR Azpiri-Lopez","year":"2021","unstructured":"Azpiri-Lopez JR, Galarza-Delgado DA, Colunga-Pedraza IJ, et al. Echocardiographic evaluation of pulmonary hypertension, right ventricular function, and right ventricular-pulmonary arterial coupling in patients with rheumatoid arthritis. Clin Rheumatol. 2021;40(7):2651\u20136. https:\/\/doi.org\/10.1007\/s10067-020-05544-z.","journal-title":"Clin Rheumatol"},{"key":"682_CR41","doi-asserted-by":"publisher","unstructured":"Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099. https:\/\/doi.org\/10.1136\/bmj.j2099.","DOI":"10.1136\/bmj.j"},{"key":"682_CR42","doi-asserted-by":"publisher","first-page":"w14656","DOI":"10.4414\/smw.2018.14656","volume":"148","author":"F Salaffi","year":"2018","unstructured":"Salaffi F, Carotti M, Di Carlo M, et al. The expanded risk score in rheumatoid arthritis (ERS-RA): performance of a disease-specific calculator in comparison with the traditional prediction scores in the assessment of the 10-year risk of cardiovascular disease in patients with rheumatoid arthrit. Swiss Med Wkly. 2018;148:w14656. https:\/\/doi.org\/10.4414\/smw.2018.14656.","journal-title":"Swiss Med Wkly"},{"issue":"18","key":"682_CR43","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA Guideline for the management of Heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in circulation. 2022;145(18):e1033] [published correction appears in circulation. 2022;146(13):e185] [published correction appears in circulation. 2023;147(14):e674]. Circulation. 2022;145(18):e895\u20131032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063.","journal-title":"Circulation"},{"issue":"18","key":"682_CR44","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/sutophagy hypothesis. Circulation. 2022;146(18):1383\u2013405. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061732.","journal-title":"Circulation"},{"issue":"7","key":"682_CR45","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108\u201323. https:\/\/doi.org\/10.1002\/art.41752.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"682_CR46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1136\/annrheumdis-2014-206305","volume":"75","author":"CC Thornton","year":"2016","unstructured":"Thornton CC, Al-Rashed F, Calay D, et al. Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation. Ann Rheum Dis. 2016;75(2):439\u201348. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206305.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"682_CR47","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/art.39039","volume":"67","author":"N Ronda","year":"2015","unstructured":"Ronda N, Greco D, Adorni MP, et al. Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthritis Rheumatol. 2015;67(5):1155\u201364. https:\/\/doi.org\/10.1002\/art.39039.","journal-title":"Arthritis Rheumatol"},{"key":"682_CR48","doi-asserted-by":"publisher","first-page":"117727191880100","DOI":"10.1177\/1177271918801005","volume":"13","author":"L Shervington","year":"2018","unstructured":"Shervington L, Darekar A, Shaikh M, Mathews R, Shervington A. Identifying reliable diagnostic\/predictive biomarkers for rheumatoid arthritis. Biomark Insights. 2018;13:1177271918801005. https:\/\/doi.org\/10.1177\/1177271918801005. Published 2018 Sep 24.","journal-title":"Biomark Insights"},{"key":"682_CR49","doi-asserted-by":"publisher","first-page":"1209490","DOI":"10.3389\/fimmu.2023.1209490","volume":"14","author":"MB Lang","year":"2023","unstructured":"Lang MB, Leung KY, Greene NDE, et al. The actions of methotrexate on endothelial cells are dependent on the shear stress-induced regulation of one carbon metabolism. Front Immunol. 2023;14:1209490. https:\/\/doi.org\/10.3389\/fimmu.2023.1209490. Published 2023 Jun 30.","journal-title":"Front Immunol"},{"issue":"8","key":"682_CR50","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1002\/art.38021","volume":"65","author":"SP Young","year":"2013","unstructured":"Young SP, Kapoor SR, Viant MR, et al. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum. 2013;65(8):2015\u201323. https:\/\/doi.org\/10.1002\/art.38021.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"682_CR51","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"PM Ridker","year":"2019","unstructured":"Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752\u201362. https:\/\/doi.org\/10.1056\/NEJMoa1809798.","journal-title":"N Engl J Med"},{"issue":"8","key":"682_CR52","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/art.23911","volume":"59","author":"DH Solomon","year":"2008","unstructured":"Solomon DH, Glynn RJ, Rothman KJ, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008;59(8):1097\u2013104. https:\/\/doi.org\/10.1002\/art.23911.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"682_CR53","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/art.22094","volume":"55","author":"S Suissa","year":"2006","unstructured":"Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum. 2006;55(4):531\u20136. https:\/\/doi.org\/10.1002\/art.22094.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"682_CR54","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1002\/art.22255","volume":"54","author":"DH Solomon","year":"2006","unstructured":"Solomon DH, Avorn J, Katz JN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(12):3790\u20138. https:\/\/doi.org\/10.1002\/art.22255.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"682_CR55","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1093\/rheumatology\/kead336","volume":"63","author":"HW Kim","year":"2024","unstructured":"Kim HW, Han M, Jung I, et al. New-onset atrial fibrillation in seropositive rheumatoid arthritis: association with disease-modifying anti-rheumatic drugs treatment. Rheumatology (Oxford). 2024;63(3):630\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kead336.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"682_CR56","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/ar2383","volume":"10","author":"A Naranjo","year":"2008","unstructured":"Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008;10(2):R30. https:\/\/doi.org\/10.1186\/ar2383.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"682_CR57","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/ard.62.9.842","volume":"62","author":"M Boers","year":"2003","unstructured":"Boers M, Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(9):842\u20135. https:\/\/doi.org\/10.1136\/ard.62.9.842.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"682_CR58","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","volume":"41","author":"C Chatre","year":"2018","unstructured":"Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac complications attributed to Chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018;41(10):919\u201331. https:\/\/doi.org\/10.1007\/s40264-018-0689-4.","journal-title":"Drug Saf"},{"issue":"4","key":"682_CR59","doi-asserted-by":"publisher","first-page":"e252327","DOI":"10.1136\/bcr-2022-252327","volume":"16","author":"A Malhotra","year":"2023","unstructured":"Malhotra A, Pathak MA, Dalia T, Vidic A. Endomyocardial biopsy-proven hydroxychloroquine-induced cardiomyopathy in a patient with rheumatoid arthritis. BMJ Case Rep. 2023;16(4):e252327. https:\/\/doi.org\/10.1136\/bcr-2022-252327. Published 2023 Apr 13.","journal-title":"BMJ Case Rep"},{"issue":"1","key":"682_CR60","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jacc.2022.04.039","volume":"80","author":"E D\u2019Andrea","year":"2022","unstructured":"D\u2019Andrea E, Desai RJ, He M, et al. Cardiovascular risks of hydroxychloroquine vs methotrexate in patients with rheumatoid arthritis. J Am Coll Cardiol. 2022;80(1):36\u201346. https:\/\/doi.org\/10.1016\/j.jacc.2022.04.039.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"682_CR61","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206624.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"682_CR62","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ahj.2008.02.025","volume":"156","author":"S Setoguchi","year":"2008","unstructured":"Setoguchi S, Schneeweiss S, Avorn J, et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008;156(2):336\u201341. https:\/\/doi.org\/10.1016\/j.ahj.2008.02.025.","journal-title":"Am Heart J"},{"issue":"10","key":"682_CR63","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.3390\/jcm9103145","volume":"9","author":"M Baniaamam","year":"2020","unstructured":"Baniaamam M, Handoko ML, Agca R, et al. The effect of Anti-TNF therapy on cardiac function in rheumatoid arthritis: an observational study. J Clin Med. 2020;9(10):3145. https:\/\/doi.org\/10.3390\/jcm9103145. Published 2020 Sep 29.","journal-title":"J Clin Med"},{"issue":"8","key":"682_CR64","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1161\/01.cir.103.8.1044","volume":"103","author":"B Bozkurt","year":"2001","unstructured":"Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001;103(8):1044\u20137. https:\/\/doi.org\/10.1161\/01.cir.103.8.1044.","journal-title":"Circulation"},{"issue":"4","key":"682_CR65","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/s1388-9842(02)00121-6","volume":"4","author":"AP Coletta","year":"2002","unstructured":"Coletta AP, Clark AL, Banarjee P, Cleland JG. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail. 2002;4(4):559\u201361. https:\/\/doi.org\/10.1016\/s1388-9842(02)00121-6.","journal-title":"Eur J Heart Fail"},{"issue":"13","key":"682_CR66","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","volume":"109","author":"DL Mann","year":"2004","unstructured":"Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept Worldwide evaluation (RENEWAL). Circulation. 2004;109(13):1594\u2013602. https:\/\/doi.org\/10.1161\/01.CIR.0000124490.27666.B2.","journal-title":"Circulation"},{"issue":"4","key":"682_CR67","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00296-006-0215-3","volume":"27","author":"J Cole","year":"2007","unstructured":"Cole J, Busti A, Kazi S. The incidence of new onset congestive heart failure and heart failure exacerbation in veteran\u2019s affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int. 2007;27(4):369\u201373. https:\/\/doi.org\/10.1007\/s00296-006-0215-3.","journal-title":"Rheumatol Int"},{"issue":"25","key":"682_CR68","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti. -TNF therapy against congestive heart failure investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107(25):3133\u201340. https:\/\/doi.org\/10.1161\/01.CIR.0000077913.60364.D2.","journal-title":"Circulation"},{"issue":"5","key":"682_CR69","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","volume":"116","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2004;116(5):305\u201311. https:\/\/doi.org\/10.1016\/j.amjmed.2003.09.039.","journal-title":"Am J Med"},{"issue":"5","key":"682_CR70","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/rheumatology\/keh610","volume":"44","author":"S Bernatsky","year":"2005","unstructured":"Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford). 2005;44(5):677\u201380. https:\/\/doi.org\/10.1093\/rheumatology\/keh610.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"682_CR71","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2174\/138161212799504759","volume":"18","author":"AY Gasparyan","year":"2012","unstructured":"Gasparyan AY, Ayvazyan L, Cocco G, Kitas GD. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des. 2012;18(11):1543\u201355. https:\/\/doi.org\/10.2174\/138161212799504759.","journal-title":"Curr Pharm Des"},{"issue":"10","key":"682_CR72","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1136\/annrheumdis-2015-207870","volume":"75","author":"J Zhang","year":"2016","unstructured":"Zhang J, Xie F, Yun H, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1813\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207870.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"682_CR73","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1161\/CIRCIMAGING.113.001193","volume":"7","author":"I Ikonomidis","year":"2014","unstructured":"Ikonomidis I, Tzortzis S, Andreadou I, et al. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging. 2014;7(4):619\u201328. https:\/\/doi.org\/10.1161\/CIRCIMAGING.113.001193.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"12","key":"682_CR74","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1707914.","journal-title":"N Engl J Med"},{"issue":"10","key":"682_CR75","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","volume":"139","author":"BM Everett","year":"2019","unstructured":"Everett BM, Cornel JH, Lainscak M, et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation. 2019;139(10):1289\u201399. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038010.","journal-title":"Circulation"},{"issue":"3","key":"682_CR76","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","volume":"46","author":"C Charles-Schoeman","year":"2016","unstructured":"Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum. 2016;46(3):261\u201371. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.05.014.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"682_CR77","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1002\/art.40911","volume":"71","author":"C Charles-Schoeman","year":"2019","unstructured":"Charles-Schoeman C, DeMasi R, Valdez H, et al. Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71(9):1450\u20139. https:\/\/doi.org\/10.1002\/art.40911.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"682_CR78","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/ard-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Buch MH, Dougados M, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance. Ann Rheum Dis. 2023;82(1):119\u201329. https:\/\/doi.org\/10.1136\/ard-2022-222259.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"682_CR79","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","volume":"78","author":"W Xie","year":"2019","unstructured":"Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019;78(8):1048\u201354. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214846.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"682_CR80","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1136\/annrheumdis-2013-205058","volume":"74","author":"I del Rinc\u00f3n","year":"2015","unstructured":"del Rinc\u00f3n I, Polak JF, O\u2019Leary DH, et al. Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1118\u201323. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205058.","journal-title":"Ann Rheum Dis"},{"issue":"9894","key":"682_CR81","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Coxib and traditional NSAID Trialists\u2019 (CNT) Collaboration, Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769\u201379. https:\/\/doi.org\/10.1016\/S0140-6736(13)60900-9.","journal-title":"Lancet"},{"issue":"4","key":"682_CR82","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/bcp.13048","volume":"82","author":"C Patrono","year":"2016","unstructured":"Patrono C. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol. 2016;82(4):957\u201364. https:\/\/doi.org\/10.1111\/bcp.13048.","journal-title":"Br J Clin Pharmacol"},{"issue":"26","key":"682_CR83","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","volume":"375","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1611593.","journal-title":"N Engl J Med"},{"issue":"4","key":"682_CR84","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1161\/CIRCOUTCOMES.109.861104","volume":"3","author":"EL Fosb\u00f8l","year":"2010","unstructured":"Fosb\u00f8l EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes. 2010;3(4):395\u2013405. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.109.861104.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"21","key":"682_CR85","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa0807646.","journal-title":"N Engl J Med"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-024-00682-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-024-00682-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-024-00682-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T10:11:55Z","timestamp":1729851115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-024-00682-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":85,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["682"],"URL":"https:\/\/doi.org\/10.1007\/s11897-024-00682-w","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,17]]},"assertion":[{"value":"4 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}